Table 2.
Current ongoing clinical trials targeting the phosphoinositide signaling cascade for the treatment of pancreatic cancer.
| Target molecule | Drug | Clinicaltrials.gov identifier | Study phase | Intervention |
|---|---|---|---|---|
| PI3K | Metformin | NCT01210911 | Phase II | Metformin+Gemcitabine+Erlotinib |
| PI3K | BKM120 | NCT01155453 | Phase I | BKM120+ GSK1120212 |
| PI3K | BKM120 | NCT01363232 | Phase I | BKM120 + MEK162 |
| PI3K | BKM120 | NCT01571024 | Phase I | BKM120 + mFOLFOX6 |
| Akt | MK2206 | NCT01783171 | Phase I | MK-2206+ Dinaciclib |
| Akt | MK2206 | NCT01658943 | Phase II | MK2206+ Fluorouracil+ Oxaliplatin+ Selumetinib |
| Akt | RX-0201 | NCT01028495 | Phase II | RX-0201+Gemcitabine |
| mTOR | Everolimus | NCT01077986 | Phase I, II | Capecitabine + Cetuximab + Everolimus |
| mTOR | Temsirolimus | NCT00075647 | Phase II | Temsirolimus |
| mTOR | Everolimus | NCT02294006 | Everolimus+ Octreotide LAR+ Metformin | |
| PI3K+mTOR | BEZ235 | NCT01337765 | Phase I | BEZ235 + MEK162 |
| CDK4/6 | Palbociclib | NCT03065062 | Phase I | Palbociclib+Gedatolisib |
| EGFR | Nimotuzumab | NCT00561990, NCT02395016 | Phase II/III | Gemcitabine ± nimotuzumab |
Data taken from https://clinicaltrials.gov/.